[November 09, 2012]

IntegenX Announces Issuance of Key Patent for Ambient Temperature Storage of DNA and RNA

IntegenX reported today that the USPTO has issued U.S. Patent # 8,283,165 to Mike Hogan, Ph.D., and GenVault Corporation, a subsidiary of IntegenX Inc. This is a fundamental patent covering formulations to create a dry state matrix for ambient temperature preservation of RNA and DNA. While significant advances in high-throughput sequencing have been made in recent years, technologies for sample storage and transport have not enjoyed the same breakthroughs. IntegenX provides GenTegra^® DNA and GenTegra RNA as chemical matrices that protect samples from hydrolysis, oxidation and microbial destruction. The GenTegra products allow scientists to collect, transport and store their samples indefinitely and safely at ambient temperatures. Further, GenTegra has been shown to protect DNA and RNA at temperature extremes - from -80 ^°C to 76 ^°C - that might be encountered during unrefrigerated shipping.

"Since the acquisition of GenVaut Corporation by IntegenX in 2011, we have continued to develop products to help customers ensure the integrity of their precious samples for forensics, next generation sequencing, cancer research and for biological investigation," said Stevan Jovanovich, President and Chief Executive Officer of IntegenX. "IntegenX is delighted that the USPTO has recognized the novel and unique character of GenTegra in granting this key patent to Dr. Hogan and GenVault Corporation."

About IntegenX Inc.

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics, next generation sequencing and biodefense applications. The company's expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented reagents for DNA and RNA preservation including GenTegra^® for stabilization and storage of purified DNA and RNA, and GenPlate^® for storage of blood samples. For more information, please visit www.integenx.com.

IntegenX, the IntegenX logo, PrepX, GenTegra and GenPlate are trademarks of IntegenX Inc.

All other names and trademarks are the property of their respective owners.

[ Back To Technology News's Homepage ]